Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.5K
RNA Interference01:23

RNA Interference

27.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.0K
Experimental RNAi02:15

Experimental RNAi

6.7K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.7K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.9K
3.9K
DNA Microarrays02:34

DNA Microarrays

19.5K
Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
19.5K
Next-generation Sequencing03:00

Next-generation Sequencing

95.5K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
95.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Versatile Applications of Antisense Oligonucleotides in Modern Medicine.

International journal of molecular sciences·2026
Same author

Addressing the needs of nano-rare patients: the n-Lorem experience.

Nucleic acids research·2026
Same author

Phosphorothioate antisense oligonucleotide induced innate immune activation is attenuated by tryptophan oxidation products.

Nucleic acids research·2026
Same author

Establishing a commercial solution for extremely rare genetic diseases.

Nature biotechnology·2026
Same author

Antisense oligonucleotide-mediated upregulation of <i>Jag1</i> ameliorates liver disease phenotypes in a mouse model of Alagille syndrome.

Molecular therapy. Nucleic acids·2025
Same author

Splice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells.

Nucleic acids research·2025

Related Experiment Video

Updated: Nov 11, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.7K

Antisense technology: an overview and prospectus.

Stanley T Crooke1, Brenda F Baker2, Rosanne M Crooke2

  • 1Ionis Pharmaceuticals, Inc., Carlsbad, CA, USA. scrooke@ionisph.com.

Nature Reviews. Drug Discovery
|March 25, 2021
PubMed
Summary
This summary is machine-generated.

Antisense oligonucleotide (ASO) therapies are advancing rapidly, with nine drugs approved for rare diseases. New ASOs show improved performance for common diseases, utilizing novel delivery methods and mechanisms.

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.0K
Detection of Human Immunodeficiency Virus Type 1 HIV-1 Antisense Protein ASP RNA Transcripts in Patients by Strand-Specific RT-PCR
08:01

Detection of Human Immunodeficiency Virus Type 1 HIV-1 Antisense Protein ASP RNA Transcripts in Patients by Strand-Specific RT-PCR

Published on: November 27, 2019

7.8K

Related Experiment Videos

Last Updated: Nov 11, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.7K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.0K
Detection of Human Immunodeficiency Virus Type 1 HIV-1 Antisense Protein ASP RNA Transcripts in Patients by Strand-Specific RT-PCR
08:01

Detection of Human Immunodeficiency Virus Type 1 HIV-1 Antisense Protein ASP RNA Transcripts in Patients by Strand-Specific RT-PCR

Published on: November 27, 2019

7.8K

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Molecular Medicine
  • Drug Development

Background:

  • Antisense oligonucleotide (ASO) technology targets RNA for disease treatment.
  • Nine ASO drugs, spanning diverse chemical classes and administration routes, are currently approved.
  • Nusinersen represents a significant commercial success in RNA-targeted therapeutics.

Purpose of the Study:

  • To review key technological advancements driving progress in antisense oligonucleotide (ASO) therapy.
  • To discuss clinical trial outcomes demonstrating the impact of these advances across various therapeutic areas.
  • To provide perspectives on future strategic considerations and the trajectory of ASO development.

Main Methods:

  • Analysis of approved antisense oligonucleotide (ASO) drugs and their characteristics (chemical class, mechanism, administration).
  • Review of late- and middle-stage clinical development pipelines, focusing on applications for common diseases.
  • Examination of recent clinical trial data to assess improvements in ASO potency, performance, and delivery.

Main Results:

  • Significant progress in medicinal chemistry, molecular mechanism understanding, and targeted delivery has enhanced ASO potency and performance.
  • ASOs in development are increasingly aimed at prevalent diseases, expanding therapeutic reach beyond rare conditions.
  • Emerging ASO formulations include novel administration routes like aerosol and oral delivery, alongside new mechanisms of action.

Conclusions:

  • Antisense oligonucleotide (ASO) technology is maturing, with approved drugs and promising candidates for a wide range of diseases.
  • Technological innovations are crucial for improving ASO efficacy, safety, and applicability to broader patient populations.
  • Strategic target selection and continued research into novel delivery and mechanisms will shape the future of ASO therapeutics.